Published:Feb 21, 2022
Recently,the Joint Prevention and Control Mechanism of the State Council approved homologousbooster vaccination ofBioKangtai'sInactivated COVID-19Vaccine(VeroCell) in China.
This means that one dose of homologous booster vaccination in previous recipients of two doses of BioKangtai's Inactivated COVID-19 Vaccine (Vero Cell). The research shows that both homologous boostervaccination and sequential boostervaccination could further improve the immune effect. For the target population,either homologous boostervaccination or sequential boostervaccination could be selected.
Shenzhen TV news:
Shenzhen Special ZoneDaily:
China, Malaysia companies inks deal on clinical trial, commercialization of COVID-19 vaccines
COVID-19: A Basic Guide to Different Vaccine Types and How They Work
With global push for COVID-19 vaccines, China aims to win friends and cut deals